Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

June 4, 2014

Trevi raises $25M for itching treatment

Submitted photo Trevi President and CEO Jennifer Good

New Haven’s Trevi Therapeutics Inc. said it has raised a Series B financing of $25 million to initiate trials for its anti-itching drug Nalbuphine ER.

The round was led by TPG Biotech, which previously invested $12.8 million in Trevi. Angel investors also participated.

Nalbuphine ER is an oral extended release formulation of nalbuphine hydrochloride, a semi-synthetic opioid which Trevi said has only previously been approved as an injectable treatment.

Trevi, which was founded in 2011 and recently completed a Phase 1 trial on patients on hemodialysis, is planning trials to test its formulation on two severe itch conditions known as uremic pruritis and prurigo nodularis. It expects to commence trials in the third quarter.

Sign up for Enews

0 Comments

Order a PDF